Nanjing Heron Pharmaceutical Co.,Ltd.

Primary Objectives: 1. To evaluate the effect of repeated administration of probenecid tablets on the pharmacokinetic characteristics of HR1405-01 injection in healthy participants; 2. To evaluate the effect of repeated administration of rifampicin capsules on the pharmacokinetic characteristics of HR1405-01 injection in healthy participants. Secondary Objectives: 1. To assess the safety and tolerability of combined administration of probenecid tablets and HR1405-01 injection in healthy participants; 2. To assess the safety and tolerability of combined administration of rifampicin capsules and HR1405-01 injection in healthy participants. Exploratory Objectives: 1. To evaluate the changes in the levels of metabolites M6 and M7 of HR1504-01 injection in the blood of healthy participants after repeated administration of probenecid tablets or rifampicin capsules; 2. To explore the effect of UGT2B7 gene polymorphism on the pharmacokinetic characteristics and DDI effect of HR1405-01 injection.

Primary objective: To evaluate the efficacy of HR1405-01 injection in treating moderate to severe pain after orthopedic surgery. Secondary objectives: To evaluate the safety of HR1405-01 injection in treating moderate to severe pain after orthopedic surgery. To evaluate the pharmacokinetic characteristics of HR1405-01 injection in treating moderate to severe pain after orthopedic surgery.

Primary Study Objectives: 1. To evaluate the pharmacokinetic characteristics of HR1405-01 injection in participants with mild to moderate hepatic impairment and normal liver function. Secondary Study Objectives: 1. To evaluate the safety of HR1405-01 injection in participants with mild to moderate hepatic impairment and normal liver function. 2. To evaluate the pharmacokinetic characteristics of the metabolite M8 of HR1405-01 injection in participants with mild to moderate hepatic impairment and normal liver function.